◎ Sugi Atlas

Atlas / Drug / Duvelisib

Duvelisib

drug
On this page

Also known as INK-1147INK-1197IPI-145DUVELISIB (IPI-145, INK1197)DuvelisibCopiktraDuvelisib (IPI-145INK1197)

Summary

Duvelisib (CHEMBL3039502) is an approved small molecule (ATC L01EM04) targeting PIK3CA, PIK3CB, and PIK3CD; indicated across 20 conditions including neoplasm and b-cell chronic lymphocytic leukemia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EM04
  • Targets: 4 (PIK3CA, PIK3CB, PIK3CD…)
  • Indications: 20 conditions
  • Clinical trials: 55
  • Chemistry: 416.9 Da · C22H17ClN6O

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3039502
NameDuvelisib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID50905713
ATCL01EM04
Molecular formulaC22H17ClN6O
Molecular weight416.9
InChIKeySJVQHLPISAIATJ-ZDUSSCGKSA-N

SMILES: C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

IUPAC name: 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one

Also known as: Duvelisib, INK-1147, INK-1197, IPI-145, DUVELISIB, DUVELISIB (IPI-145, INK1197), Duvelisib; Copiktra, Duvelisib (IPI-145; INK1197), duvelisib

Parent form; salt/anhydrous children: CHEMBL5315125

Patent coverage: 2,039 distinct patent families (5,332 SureChEMBL compound mentions), from 8 matched compound structure(s). One matched structure accounts for 4,787 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PIK3CAphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaInhibition5.842.7%P42336
PIK3CBphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit betaInhibition7.075%P42338
PIK3CDphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit deltaInhibition8.66%O00329
PIK3CGphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gammaInhibition7.570.7%P48736

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Thromboxane A2 receptor, PI3-kinase p110-alpha/p85-alpha, PI3-kinase p110-delta/p85-alpha, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, 5-hydroxytryptamine receptor 2A, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, PI3K p110 beta/p85 alpha, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/gamma isoform, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, Bile salt export pump.

Bioactivity

ChEMBL activities: 41 potent at pChembl ≥ 5 of 45 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PIK3CD9.62IC500.24nMCHEMBL_ACT_25556643
PIK3CD9IC501nMCHEMBL_ACT_19041450
PIK3CD9IC501nMCHEMBL_ACT_19041569
PIK3CG8.7IC502nMCHEMBL_ACT_19041427
PIK3CD8.64IC502.3nMCHEMBL_ACT_18769660
PIK3CG8.6IC502.5nMCHEMBL_ACT_18952540
PIK3CD8.6IC502.5nMCHEMBL_ACT_19036925
PIK3CD8.6IC502.5nMCHEMBL_ACT_24766729
PIK3CD8.6IC502.5nMCHEMBL_ACT_24862057
PIK3CD8.6IC502.5nMCHEMBL_ACT_26047648
PIK3CD8.6IC502.5nMCHEMBL_ACT_26187201
PIK3CG8.54IC502.9nMCHEMBL_ACT_16673449
PIK3CD8.3EC505nMCHEMBL_ACT_26047686
PIK3R18.1IC508nMCHEMBL_ACT_19041473
PIK3CG7.92IC5012nMCHEMBL_ACT_18769663
PIK3CD7.85IC5014nMCHEMBL_ACT_19041627
PIK3CD7.85IC5014nMCHEMBL_ACT_26187196
PIK3CG7.82IC5015nMCHEMBL_ACT_19041631
PIK3CB7.68EC5021nMCHEMBL_ACT_26047682
PIK3CD7.57IC5027nMCHEMBL_ACT_18952532
PIK3CG7.57IC5027nMCHEMBL_ACT_19036926
PIK3CG7.57IC5027nMCHEMBL_ACT_24766721
PIK3CG7.57IC5027nMCHEMBL_ACT_25847386
PIK3CG7.57IC5027nMCHEMBL_ACT_26047647
PIK3CG7.57IC5027nMCHEMBL_ACT_26187200
PIK3CG7.56IC5027.4nMCHEMBL_ACT_24862058
PIK3R17.31IC5049nMCHEMBL_ACT_18769657
PIK3CG7.3IC5050nMCHEMBL_ACT_25556630
Q9JHG77.29IC5051nMCHEMBL_ACT_26187194
Q9JHG77.14EC5072nMCHEMBL_ACT_26047684
PIK3CB7.07IC5085nMCHEMBL_ACT_18952521
PIK3CB7.07IC5085nMCHEMBL_ACT_26187199
PIK3CD7.02IC5096nMCHEMBL_ACT_19474662
PIK3CD7IC50100nMCHEMBL_ACT_19474663
PIK3CB6.52IC50301nMCHEMBL_ACT_26187192
PIK3R16.4IC50400nMCHEMBL_ACT_18769654
PIK3CA6.15EC50711nMCHEMBL_ACT_26047680
PIK3CA5.79IC501602nMCHEMBL_ACT_18952525
PIK3CA5.79IC501602nMCHEMBL_ACT_26047646
PIK3CA5.79IC501602nMCHEMBL_ACT_26187198
PIK3CD5.66IC502206nMCHEMBL_ACT_19041633

Target pathways

Aggregated over 4 target gene(s): PIK3CA, PIK3CB, PIK3CD, PIK3CG.

Top Reactome pathways

62 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling4PIK3CA, PIK3CB, PIK3CD, PIK3CG
Synthesis of PIPs at the plasma membrane4PIK3CA, PIK3CB, PIK3CD, PIK3CG
Constitutive Signaling by Aberrant PI3K in Cancer4PIK3CA, PIK3CB, PIK3CD, PIK3CG
CD28 dependent PI3K/Akt signaling4PIK3CA, PIK3CB, PIK3CD, PIK3CG
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling4PIK3CA, PIK3CB, PIK3CD, PIK3CG
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)4PIK3CA, PIK3CB, PIK3CD, PIK3CG
Co-stimulation by ICOS4PIK3CA, PIK3CB, PIK3CD, PIK3CG
GPVI-mediated activation cascade3PIK3CA, PIK3CB, PIK3CG
Interleukin-3, Interleukin-5 and GM-CSF signaling3PIK3CA, PIK3CB, PIK3CD
RET signaling3PIK3CA, PIK3CB, PIK3CD
Interleukin receptor SHC signaling3PIK3CA, PIK3CB, PIK3CD
Regulation of signaling by CBL3PIK3CA, PIK3CB, PIK3CD
Signaling by CSF1 (M-CSF) in myeloid cells3PIK3CA, PIK3CB, PIK3CD
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells3PIK3CA, PIK3CB, PIK3CD
PI3K Cascade2PIK3CA, PIK3CB
IRS-mediated signalling2PIK3CA, PIK3CB
Downstream signal transduction2PIK3CA, PIK3CB
PI3K/AKT activation2PIK3CA, PIK3CB
Signaling by ALK2PIK3CA, PIK3CB
Downstream TCR signaling2PIK3CA, PIK3CB
Role of phospholipids in phagocytosis2PIK3CA, PIK3CB
Tie2 Signaling2PIK3CA, PIK3CB
DAP12 signaling2PIK3CA, PIK3CB
Role of LAT2/NTAL/LAB on calcium mobilization2PIK3CA, PIK3CB
Nephrin family interactions2PIK3CA, PIK3CB
VEGFA-VEGFR2 Pathway2PIK3CA, PIK3CB
RAF/MAP kinase cascade2PIK3CA, PIK3CB
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants2PIK3CA, PIK3CB
Signaling by PDGFRA extracellular domain mutants2PIK3CA, PIK3CB
Signaling by ALK fusions and activated point mutants2PIK3CA, PIK3CB
Signaling by LTK in cancer2PIK3CA, PIK3CB
Signaling by LTK2PIK3CA, PIK3CB
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants1PIK3CA
PI3K events in ERBB4 signaling1PIK3CA
Signaling by SCF-KIT1PIK3CA
GAB1 signalosome1PIK3CA
Signaling by cytosolic FGFR1 fusion mutants1PIK3CA
PI3K events in ERBB2 signaling1PIK3CA
G beta:gamma signalling through PI3Kgamma1PIK3CG
G alpha (q) signalling events1PIK3CA
Constitutive Signaling by EGFRvIII1PIK3CA
PI-3K cascade:FGFR11PIK3CA
PI-3K cascade:FGFR21PIK3CA
PI-3K cascade:FGFR31PIK3CA
PI-3K cascade:FGFR41PIK3CA
Signaling by FGFR2 in disease1PIK3CA
Signaling by FGFR4 in disease1PIK3CA
Signaling by FGFR1 in disease1PIK3CA
Signaling by FGFR3 in disease1PIK3CA
MET activates PI3K/AKT signaling1PIK3CA

Dominant GO biological processes

GO termTargets
cell migration4
phosphatidylinositol-3-phosphate biosynthetic process4
phosphatidylinositol 3-kinase/protein kinase B signal transduction4
phosphatidylinositol phosphate biosynthetic process4
phosphatidylinositol-mediated signaling4
lipid metabolic process4
chemotaxis3
positive regulation of endothelial cell migration3
innate immune response3
angiogenesis2
platelet activation2
vascular endothelial growth factor signaling pathway2
T cell receptor signaling pathway2
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction2
negative regulation of fibroblast apoptotic process2

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
B-cell chronic lymphocytic leukemia4MONDO:0004948EFO:0000095
follicular lymphoma4MONDO:0018906MONDO:0018906

15 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
leukemia2MONDO:0005059EFO:0000565
rheumatoid arthritis2MONDO:0008383EFO:0000685
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
asthma2MONDO:0004979MONDO:0004979
lymphoma2MONDO:0005062EFO:0000574
lymphoid leukemia2MONDO:0005402EFO:0004289
liver disorder1MONDO:0005154EFO:0001421
melanoma1MONDO:0005105EFO:0000756
Sezary syndrome1MONDO:0017844EFO:1000785
mycosis fungoides1MONDO:0009691EFO:1001051
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 55.

Phase distribution

PhaseTrials
PHASE120
PHASE219
PHASE1/PHASE28
PHASE35
Not specified2
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06522737PHASE3RECRUITINGA Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
NCT02004522PHASE3COMPLETEDA Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
NCT02049515PHASE3COMPLETEDA Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
NCT02204982PHASE3TERMINATEDStudy of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
NCT02576275PHASE3WITHDRAWNA Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
NCT02158091PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
NCT03534323PHASE1/PHASE2ACTIVE_NOT_RECRUITINGDuvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
NCT03961672PHASE2ACTIVE_NOT_RECRUITINGIntermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05675813PHASE1/PHASE2RECRUITINGGenotype-guided Treatment in Newly Diagnosed PTCL
NCT05976997PHASE2RECRUITINGProspective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
NCT06810778PHASE1/PHASE2RECRUITINGDuvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT07293403PHASE2NOT_YET_RECRUITINGDuvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
NCT01653756PHASE2COMPLETEDA Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects
NCT01851707PHASE2COMPLETEDA Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
NCT01882803PHASE2COMPLETEDA Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
NCT02028039PHASE2WITHDRAWNIPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02391545PHASE1/PHASE2TERMINATEDA Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
NCT02605694PHASE2WITHDRAWNDuvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
NCT02711852PHASE2COMPLETEDA Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
NCT03370185PHASE2WITHDRAWNPhase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
NCT03372057PHASE2COMPLETEDA Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT04038359PHASE2COMPLETEDA Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
NCT04193293PHASE1/PHASE2TERMINATEDA Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
NCT04209621PHASE2TERMINATEDDuvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04331119PHASE2TERMINATEDDuvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
NCT04372602PHASE2COMPLETEDDuvelisib to Combat COVID-19
NCT04487886PHASE2COMPLETEDDuvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)
NCT04688658PHASE1/PHASE2TERMINATEDDuvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
NCT04707079PHASE2UNKNOWNA Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
NCT04803201PHASE2SUSPENDEDTesting the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
NCT05057247PHASE2COMPLETEDDuvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
NCT05508659PHASE1/PHASE2UNKNOWNA Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors
NCT04652960PHASE1ACTIVE_NOT_RECRUITINGDuvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
NCT05010005PHASE1RECRUITINGA Study of Ruxolitinib and Duvelisib in People With Lymphoma
NCT05044039PHASE1ACTIVE_NOT_RECRUITINGDuvelisib Following Chimeric Antigen Receptor T-Cell Therapy
NCT07001384PHASE1RECRUITINGA Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
NCT01476657PHASE1TERMINATEDA Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
NCT01549106PHASE1COMPLETEDIPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
NCT01836861PHASE1COMPLETEDIPI-145 ADME and Absolute Bioavailability Study
NCT01871675PHASE1COMPLETEDStudy of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
NCT01925911PHASE1COMPLETEDPhase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
NCT01947777PHASE1COMPLETEDPhase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
NCT02095587PHASE1COMPLETEDDuvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
NCT02292225PHASE1TERMINATEDDuvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
NCT02307461PHASE1COMPLETEDBioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
NCT02598570PHASE1COMPLETEDStudy Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
NCT02640833PHASE1WITHDRAWNA Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
NCT02783625PHASE1COMPLETEDTrial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
NCT03892044PHASE1COMPLETEDDuvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
NCT04639843PHASE1WITHDRAWNDoxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
NCT04836832PHASE1WITHDRAWNAcalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
NCT05065866PHASE1COMPLETEDDuvelisib in Combination With BMS-986345 in Lymphoid Malignancy
NCT04890236EARLY_PHASE1COMPLETEDDuvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
NCT05923502Not specifiedNOT_YET_RECRUITING(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin’s Lymphoma (NHL)
NCT04342117Not specifiedTERMINATEDObservational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

72 molecules share ≥1 primary target. Top 72 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
IDELALISIBChEMBL + PubChemPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
INAVOLISIBChEMBL + PubChemPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
ALPELISIBChEMBLPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
COPANLISIBChEMBLPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
LENIOLISIBChEMBLPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
BUPARLISIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
DACTOLISIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
GEDATOLISIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
LESTAURTINIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
TASELISIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
AMG-319ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
APITOLISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
AZD-6482ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
BGT-226 FREE BASEChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
BIMIRALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
EGANELISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
FIMEPINOSTATChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
IZORLISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
NEMIRALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
OMIPALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
ONATASERTIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
PAXALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
PF-04691502ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
PICTILISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
PILARALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
ROGINOLISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
SAMOTOLISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
SAPANISERTIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
SERABELISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
TG100-115ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
VISTUSERTIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
VOXTALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
ZSTK-474ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
AfatinibPubChemApprovedPIK3CA, PIK3CB, PIK3CD, PIK3CG
PazopanibPubChemApprovedPIK3CA, PIK3CB, PIK3CD, PIK3CG
SelumetinibPubChemApprovedPIK3CA, PIK3CB, PIK3CD, PIK3CG
SUNITINIBChEMBLPhase 4 (approved)PIK3CA, PIK3CD, PIK3CG
DEZAPELISIBChEMBLPhase 2PIK3CB, PIK3CD, PIK3CG
QUISINOSTATChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD
RISOVALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD
SONOLISIBChEMBLPhase 2PIK3CA, PIK3CD, PIK3CG
GefitinibPubChemApprovedPIK3CB, PIK3CD, PIK3CG
DASATINIBChEMBLPhase 4 (approved)PIK3CA, PIK3CD
FEDRATINIBChEMBLPhase 4 (approved)PIK3CA, PIK3CG
UMBRALISIBChEMBLPhase 4 (approved)PIK3CD, PIK3CG
RESVERATROLChEMBLPhase 3PIK3CA, PIK3CB
ACALISIBChEMBLPhase 2PIK3CD, PIK3CG
AMDIZALISIBChEMBLPhase 2PIK3CD, PIK3CG
AZD-8154ChEMBLPhase 2PIK3CA, PIK3CD
BI-2536ChEMBLPhase 2PIK3CA, PIK3CD
GSK-2636771ChEMBLPhase 2PIK3CB, PIK3CD
OSI-027ChEMBLPhase 2PIK3CA, PIK3CG
SELETALISIBChEMBLPhase 2PIK3CD, PIK3CG
TENALISIBChEMBLPhase 2PIK3CD, PIK3CG
BELINOSTATChEMBLPhase 4 (approved)PIK3CA
CAFFEINEChEMBLPhase 4 (approved)PIK3CD
MIDOSTAURINChEMBLPhase 4 (approved)PIK3CA
ROMIDEPSINChEMBLPhase 4 (approved)PIK3CA
THEOPHYLLINEChEMBLPhase 4 (approved)PIK3CD
EPIGALOCATECHIN GALLATEChEMBLPhase 3PIK3CA
IPATASERTIBChEMBLPhase 3PIK3CA
PARSACLISIBChEMBLPhase 3PIK3CD
POVORCITINIBChEMBLPhase 3PIK3CD
QUERCETINChEMBLPhase 3PIK3CG
BERZOSERTIBChEMBLPhase 2PIK3CA
CC-115ChEMBLPhase 2PIK3CA
LINPERLISIBChEMBLPhase 2PIK3CD
MMV-048ChEMBLPhase 2PIK3CA
NARAZACICLIBChEMBLPhase 2PIK3CD
R-406ChEMBLPhase 2PIK3CD
RAFOXANIDEChEMBLPhase 2PIK3CA

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot